Clinical Trials | February 24, 2026
Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The data highlights its RSV vaccine cuts hospitalizations in older adults
Subscribe To Our Newsletter & Stay Updated
